2024 Annual Report
I’m proud to share with you TAG’s 2024 Annual Report. Last year already seems long ago with all the attacks on research and health care, domestic and international, which are currently taking place under the new administration...
WEBINAR: TB Treatment’s New Frontier: Orienting Community to Long-Acting Injectables for TB
On June 5, 2025, TAG and WHO cohosted a webinar orienting people to long-acting injectables for TB treatment and prevention. Long-acting Injectables (LAIs) have the potential to revolutionize treatment for TB and other infectious diseases.
2025 Comments Delivered at the WHO Director General’s TB Vaccine Accelerator Council
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 3rd meeting of the WHO Director-General’s TB Vaccine Accelerator Council on May 20, 2025 in Geneva, Switzerland.
U.S. Funding Cuts Threaten 39 Research Sites in South Africa Putting Scientific Advancements and Hard Won Progress Against TB and HIV at Risk
Lifesaving scientific research on prevention, testing, treatment and care for people living with HIV and tuberculosis (TB) in South Africa is under serious threat due to funding suspensions and grant terminations from the United States (US) government.
South Africa’s TB and HIV Research at Risk: A Call to Catalyze Urgent Action by Funders
Developed by TAG, Médecins Sans Frontières, and the South African Medical Research Council, this issue brief provides information about TB and HIV clinical trials and research programs impacted by U.S. government funding disruptions...
LONGEVITY Community Engagement: Perspectives of People with HCV and TB Lived Experience and Healthcare Providers on Potential Long-Acting Therapies
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.
Inside the Fight: A Day in the Life of TAG’s TB Team
What does TAG's work look like in action? Here we step into a day in the life of our TB program co-directors, Mike Frick and Lindsay McKenna, to see how their advocacy for better TB research and policy — made possible by your support — are driving meaningful change to save lives and empower communities affected by TB.
Speed-Up, Scale-Up TB Testing: A Two-Part Webinar Series Focused on the Asia-Pacific Region
TAG, APCASO, and Diagnostics Equity Consortium (DEC) hosted a two-part webinar series exploring the evolving TB diagnostic landscape and strategies to increase TB testing coverage, with a specific focus on the South-East Asia and Western-Pacific regions.
Diagnostics Equity Consortium: Close the Deadly TB Testing Gaps in Asia-Pacific
TAG is one of the endorsers of this Diagnostic Equity Consortium statement and call to action advocating for scaling up access to diagnostics to address the deadly gaps in TB testing.
Tuberculosis Research at the National Institutes of Health – Saving Lives, Shrinking Costs, Fueling American Jobs and Innovation
This policy brief describes the crucial role NIH plays in supporting research on new products to prevent, diagnose, and cure TB. This research is especially important at a time when new forms of drug resistance are emerging globally, and rates of TB are rising in the U.S. With continued and increased funding, NIH can protect Americans from the growing threat of TB at home and abroad.